November 14, 2011 - EX-99.1 - 8-K/A: Current report filing

Exhibit 99.1

Claros Diagnostics, Inc.

(A Development Stage Company)

Consolidated Financial Statements

and

Supplemental Information

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

LOGO

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

AND

SUPPLEMENTAL INFORMATION

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

AND

SUPPLEMENTAL INFORMATION

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

TABLE OF CONTENTS


		Page
Independent Auditors Report		1

Consolidated Financial Statements:

Consolidated Balance Sheet		2

Consolidated Statements of Operations		3

Consolidated Statements of Changes in Equity and Comprehensive Income		4-6

Consolidated Statements of Cash Flows		7

Notes to Consolidated Financial Statements		8-17

Supplemental Information:

Independent Auditors Report on Consolidating and Supplemental Information		19

Consolidating Balance Sheet		20

Consolidating Statement of Operations		21

Consolidating Schedule of General and Administrative Expenses		22

LOGO

INDEPENDENT AUDITORS REPORT

Board of Directors and Stockholders

Claros Diagnostics, Inc.

Woburn, Massachusetts

We have audited the accompanying consolidated balance sheet of Claros Diagnostics, Inc. (A Development Stage Company) as of December 31, 2010 and the related consolidated statements of operations, changes in equity and comprehensive income and cash flows for the year then ended and for the period October 27, 2004 (Inception) to December 31, 2010. These consolidated financial statements are the responsibility of the Companys management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Claros Diagnostics, Inc. (A Development Stage Company) as of December 31, 2010 and the results of their operations and their cash flows for the year then ended and for the period October 27, 2004 (Inception) to December 31, 2010, in conformity with accounting principles generally accepted in the United States of America.

LOGO

Kirkland Albrecht & Fredrickson, LLC

Braintree, Massachusetts

June 26, 2011

LOGO

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Balance Sheet

December 31, 2010

Page 2


ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	111,209
Refundable taxes		554
Prepaid expenses		18,552

Total current assets		130,315
PROPOERTY AND EQUIPMENT, AT COST:
Equipment		489,718
Leasehold improvements		117,816
Computer		74,302
Furniture and fixtures		43,283

		725,119
Less accumulated depreciation		320,904

Property and equipment, net		404,215
OTHER ASSETS
Deposits		16,671
Accrued interest receivable from stockholder		5,950

Total other assets		22,621

	$	557,151

LIABILITIES AND DEFICIT
CURRENT LIABILITIES:
Convertible promissory note	$	2,000,000
Accounts payable		141,404
Accrued expenses		204,641

Total current liabilities		2,346,045

DEFICIT:
Preferred stock, $0.001 par value, 14,128,753 shares authorized, 9,528,753 issued and outstanding (liquidation preference of $14,504,970)		2,714,498
Common stock, $0.001 par value, 28,000,000 share authorized, 4,005,555 shares issued and outstanding		4,006
Additional paid-in capital		12,052,488
Stock subscription receivable		(40,515	)
Deficit accumulated during the development stage		(16,519,371	)

Total deficit		(1,788,894	)

Total liabilities and deficit	$	557,151

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statements of Operations

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 3


	2010			Cumulative for the Period October 27, 2004 (Inception) to December 31, 2010
REVENUES	$			$

OPERATING EXPENSES:
General and administrative		3,193,498			9,605,891
Research and development		1,051,374			4,914,679
Marketing		12,527			12,527

		4,257,399			14,533,097

Operating loss		(4,257,399	)		(14,533,097	)
OTHER INCOME (EXPENSE):
Grant income		244,479			265,269
Interest expense		(64,000	)		(64,530	)
Dividend income		995			475,080
Interest income		112			11,285
Competition income					26,000

Total other income, net		181,586			713,104
Net loss		(4,075,813	)		(13,819,993	)
PROVISION FOR INCOME TAXES
Current
Deferred


Net income (loss) attributable to noncontrolling interest		(1,722	)		230
Net loss attributable to Claros Diagnostics, Inc.	$	(4,077,535	)	$	(13,819,763	)

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statements of Changes in Equity and Comprehensive Income

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 4


	Preferred Stock				Common Stock				Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
	Shares		Amount		Shares		Amount		Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
Balance at October 27, 2004 (Date of inception)			$				$		$		$			$			$			$			$
COMPREHENSIVE INCOME (LOSS)
Net Loss
Foreign currency translation adjustment

COMPREHENSIVE LOSS
Issuance of 2,925,000 shares of common stock						2,925,000		2,925																2,925

Balance, December 31, 2004						2,925,000		2,925																2,925
COMPREHENSIVE LOSS
Net Loss															(3,429	)								(3,429	)
Foreign currency translation adjustment

COMPREHENSIVE LOSS
Issuance of 7,500 shares of common stock						7,500		8																8

Balance, December 31, 2005						2,932,500		2,933							(3,429	)								(496	)
Sale of Subsidiary shares to non-controlling interest																					406			406
COMPREHENSIVE LOSS
Net Loss															(158,630	)					(49	)		(158,679	)
Foreign currency translation adjustment																		(396	)		150			(246	)

COMPREHENSIVE LOSS																		(396	)					(158,925	)
Issuance of 594,097 shares of common stock						594,097		594		40,203														40,797
Stock subscription receivable												(40,515	)											(40,515	)
Issuance of 6,298,667 shares of Series A preferred stock		6,298,667		6,298						7,793,702														7,800,000
Accretion of dividends on Series A preferred stock				16,477											(16,477	)

Balance, December 31, 2006		6,298,667		22,775		3,526,597		3,527		7,833,905		(40,515	)		(178,536	)		(396	)		507			7,641,267

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statements of Changes in Stockholders Equity and Comprehensive Incomecontinued

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 5


	Preferred Stock				Common Stock				Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
	Shares		Amount		Shares		Amount		Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
Balance, December 31, 2006		6,298,667		22,775		3,526,597		3,527		7,833,905		(40,515	)		(178,536	)		(396	)		507			7,641,267
COMPREHENSIVE INCOME (LOSS)
Net Loss															(1,721,663	)					(1,326	)		(1,722,989	)
Foreign currency translation adjustment																		2,666			(34	)		2,632

COMPREHENSIVE LOSS																		2,270						(1,720,357	)
Accretion of dividends on Series A preferred stock				546,724											(546,724	)
Incentive option based compensation										39,001														39,001

Balance, December 31, 2007		6,298,667		569,499		3,526,597		3,527		7,872,906		(40,515	)		(2,446,923	)		2,270			(853	)		5,959,911
COMPREHENSIVE INCOME (LOSS)
Net Loss															(4,092,764	)					(284	)		(4,093,048	)
Foreign currency translation adjustment																		2,492			(111	)		2,381

COMPREHENSIVE LOSS																		4,762						(4,090,667	)
Issuance of 328,055 shares of common stock						328,055		328		42,319														42,647
Accretion of dividends on Series A preferred stock				546,724											(546,724	)
Stock-based based compensation expense										47,909														47,909

Balance, December 31, 2008		6,298,667		1,116,223		3,854,652		3,855		7,963,134		(40,515	)		(7,086,411	)		4,762			(1,248	)		1,959,800
COMPREHENSIVE INCOME (LOSS)
Net Loss															(3,765,742	)					(347	)		(3,766,089	)
Foreign currency translation adjustment																		(158	)		(149	)		(307	)

COMPREHENSIVE LOSS																		4,604						(3,766,396	)
Issuance of 3,230,086 shares of Series A preferred stock		3,230,086		3,230						3,996,770														4,000,000
Issuance of 131,220 shares of common stock						131,220		131		16,927														17,058
Accretion of dividends on Series A preferred stock				767,949											(767,949	)
Incentive option based compensation										36,097														36,097

Balance, December 31, 2009		9,528,753		1,887,402		3,985,872		3,986		12,012,928		(40,515	)		(11,620,102	)		4,604			(1,744	)		2,246,559

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statements of Changes in Stockholders Equity and Comprehensive Incomecontinued

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 6


	Preferred Stock				Common Stock				Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
	Shares		Amount		Shares		Amount		Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
Balance, December 31, 2009		9,528,753		1,887,402		3,985,872		3,986		12,012,928		(40,515	)		(11,620,102	)		4,604			(1,744	)		2,246,559
COMPREHENSIVE INCOME (LOSS)
Net income (loss)															(4,077,535	)					1,722			(4,075,813	)
Foreign currency translation adjustment																		1,060			(280	)		780

COMPREHENSIVE LOSS																		5,664						(4,075,033	)
Issuance of 19,683 shares of common stock						19,683		20		2,539														2,559
Accretion of dividends on Series A preferred stock				827,096											(827,096	)
Liquidation of subsidiary															5,362			(5,664	)		302
Incentive option based compensation										37,021														37,021

Balance, December 31, 2010		9,528,753	$	2,714,498		4,055,555	$	4,006	$	12,052,488	$	(40,515	)	$	(16,519,371	)	$			$			$	(1,788,894	)

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statements of Cash Flows

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 7


	2010			Cumulative for the Period October 27, 2004 (Inception) to December 31, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(4,075,813	)	$	(13,819,993	)
Adjustments to reconcile net loss to net cash provided (used) by operating activities:
Incentive option based compensation		37,021			160,028
Depreciation		119,770			320,906
Changes in assets and liabilities:
(Increase) decrease in:
Accrued interest receivable from a stockholder		(95	)		(5,950	)
Prepaid expenses and other current assets		(2,708	)		(18,552	)
Refundable taxes		13,599			(554	)
Decrease (increase) in:
Accounts payable		11,088			154,556
Accrued expenses and other current liabilities		52,954			206,406

Net cash used by operating activities		(3,844,184	)		(13,003,153	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment		(167,127	)		(725,119	)
Deposits					(16,671	)

Net cash used by investing activities		(167,127	)		(741,790	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory note		2,000,000			2,000,000
Payments on stockholder notes payable					(24,877	)
Advances of stockholder notes payable					24,877
Proceeds from issuance of common stock		2,559			65,479
Proceeds from issuance of preferred stock					11,800,000

Net cash provided by financing activities		2,002,559			13,865,479

EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS		779			(9,327	)

NET INCREASE (DECREAE IN CASH AND CASH EQUIVALENTS		(2,007,973	)		111,209
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		2,119,182

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	111,209		$	111,209

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the year for:
Interest
Income taxes	$			$	980

	$			$

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 8

1.	ORGANIZATION

The Company was formed under the name Claros Diagnostics, Inc. (the Company). The Company was incorporated on October 27, 2004 under the general laws of the state of Delaware. Its principal business activity is to develop, manufacture and sell medical diagnostic devices to customers within the United States. The Company is located in Woburn, Massachusetts.

Claros Diagnostics, SARL (SARL), was a majority owned subsidiary in Switzerland (Neuchatel) and was organized on August 7, 2006. Its principal business activity was to develop, manufacture and sell medical diagnostic devices to customers in Europe. On December 16, 2010, SARLs board of directors voted to liquidate its entity.

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation The accompanying consolidated financial statements for the year ended December 31, 2010 and for the period October 24, 2004 (inception) to December 31, 2010 are prepared in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic Consolidation. These consolidated financial statements include the accounts of the Company and its majority owned subsidiary SARL for the year ended December 31, 2010. All significant inter-company balances and transactions have been eliminated.

Foreign Subsidiary Statements of the accounts of Claros Diagnostics, SARL are translated into U.S. dollars at the prevailing rate of exchange at the balance sheet date; whereas revenue and expense categories have been translated at the average of foreign exchange rates prevailing throughout the fiscal year. There are no net assets of the foreign subsidiary included in the consolidated balance sheets at December 31, 2010 because the entity was liquidated during the year. The subsidiary recorded a net loss of $34,436 for the year ended December 31, 2010.

Use of Estimates The preparation of consolidated financial statements in conformity with generally accepted accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of consolidated revenues and expenses during the reporting period. Actual results could differ from those estimates. These differences could be significant.

Cash and Cash Equivalents The Company and SARL consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company frequently holds cash in demand accounts at the bank in excess of federally insured amounts.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 9

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIEScontinued

Property and Equipment The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Maintenance, routine repairs and minor replacements are charged against current earnings as incurred, while those items which substantially improve or extend the lives of existing assets are capitalized. Depreciation is computed using straight-line method. Estimated useful lives are as follows:


Asset		Years
Equipment		5
Leasehold improvements		5
Computer		3
Furniture and fixtures		7

Valuation of Long-lived Assets The Companys long-lived and certain identifiable intangible assets are reviewed for impairment in accordance with the guidance of the Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) Topic Property, Plant, and Equipment. This Topic, together with FASB ASC Topic Intangibles Goodwill and Other, requires that long-lived and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived or identifiable intangible asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset. Assets to be disposed of are reportable at the lower of the carrying amount or fair value, less costs to sell. At December 31, 2010, the Company has determined that no long-lived or certain identifiable assets are impaired.

Patent Legal The legal and professional costs incurred by the Company to acquire its patent rights have been expensed as part of operating expenses since inception. At December 31, 2010, the Company has determined that these expenses have not met the criteria to be capitalized. For the year ended December 31, 2010 and the period October 27, 2004 (Inception) to December 31, 2010 patent legal costs were $163,068 and $508,883, respectively.

Income Taxes The Company follows the FASB ASC Topic Income Taxes, in reporting deferred income taxes. The FASB ASC Topic Income Taxes requires a company to recognize deferred tax liabilities and assets for expected future income tax consequences of events that have been recognized in the Companys financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 10

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIEScontinued

Income Taxes...continued The Company accounts for uncertain tax positions in accordance with FASB ASC Topic Income Taxes. FASB ASC Topic Income Taxes prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The Topic also provides guidance on recognition, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As of December 31, 2010, management is not aware of any uncertain tax positions taken by the Company.

Exchange Rate Gains and Losses Aggregate transaction gains and losses on foreign exchange rates included in consolidated net loss for the year ended December 31, 2010 were not material.

Research and Development Research and development costs are charged to expense as incurred in accordance with FASB ASC Topic Research and Development. Research and development costs include consulting, material and supplies. For the year ended December 31, 2010 and the period October 27, 2004 (Inception) to December 31, 2010 research and development costs were $1,051,374 and $4,914,679, respectively.

Comprehensive Income Comprehensive income for the Company and SARL consisted of foreign currency translation adjustments. Accumulated other comprehensive income is disclosed as a separate component of stockholders equity and consists entirely of foreign currency translation. At December 31, 2010 there was no foreign currency translation due to the liquidation of the subsidiary SARL.

Incentive Option Plan The Company has an incentive option plan which is more fully described in Note 6. FASB ASC Topic Compensation Stock Compensation, requires that the cost resulting for all share-based payment transactions be recognized in the consolidated financial statements. This Topic requires the entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide services in exchange for the award of the vesting period. This Topic permits entities to use any option-pricing model that meets the fair value objective of the Statement. Compensation cost on options granted has been measured using the fair value of an award on the grant date using the Black-Scholes valuation model, and is recognized in the income statement over the service period, which is usually the vesting period of the option.

Subsequent Events  The Company has evaluated all events subsequent to the consolidated balance sheet date of December 31, 2010, through the date which the financial statements were available to be issued, June 26, 2011, and has determined that there are no subsequent events that require disclosure under FASB ASC Topic Subsequent Events.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 11

3.	LIQUIDATION OF SUBSIDIARY

Effective December 16, 2010, SARLs board of directors voted to liquidate this entity. The assets of the subsidiary were liquidated before December 31, 2010. The Company received $14,294 from the subsidiary upon liquidation and recorded a loss on liquidation of $6,172.

4.	PROVISION FOR INCOME TAXES

Amounts for deferred tax asset and liability are as follows:


Deferred tax asset	$	6,831,095
Valuation allowance		(6,831,095	)

	$

The deferred tax asset consists of the following temporary differences:


Depreciation	$	(58,800	)
Net operating loss carryforward		5,364,255
R & D credits		1,459,920
Stock option		65,720
Valuation allowance		(6,831,095	)

	$

At December 31, 2010, the Company has available net operating losses (NOL) carry forward for federal and state income tax purposes of approximately $12,747,759 and $13,062,826, respectively, which expire, if unused at various times through 2030. The Companys ability to utilize these NOLs may be limited under Internal Revenue Code Section 382.

The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefit from deductible temporary differences and net operating loss carry forwards cannot be sufficiently assured at December 31, 2010.

5.	RELATED PARTY TRANSACTIONS

Stock Subscription Receivable  At December 31, 2010, the Company has a promissory note receivable from a stockholder of the Company for his stock subscription for an amount of $40,515. The amount is included as a reduction of the equity on the accompanying consolidated balance sheet. The note bears interest at the Applicable Federal Rate and shall be compounded annually. At December 31, 2010, there was $5,950 of accrued interest receivable from a stockholder, included in the other assets on the accompanying consolidated balance sheet. The principal loan amount and the accrued interest are due December 2011.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 12

6.	CONVERTIBLE PROMISSORY NOTE

On June 21, 2010, the company entered into a $ 5,000,000 convertible promissory note agreement with some of the Companys stockholders. The note borrowings can be made at the discretion of the Company in tranches. Each tranche bears interest at 8% from the date it is accessed. All notes are due on or after December 31, 2011. Interest and Principle can be pre-paid at the election of the Company. At December 31, 2010, $2,000,000 of the convertible promissory note has been accessed, and accrued interest on the convertible promissory note amounted to $64,000.

Each note holder has certain conversion rights, detailed in the convertible promissory notes, which vary based on meeting certain financial criteria as follows:

In the event the Company receives other financing, outstanding principle and interest will convert into shares of the same class and series of capital stock of the Company issued to the investors in the financing at a discount price for these shares.

In the event the Company is sold prior to the closing of any financing, all outstanding notes shall be cancelled upon the closing of such sale and each note holder will have the option to either receive a multiple of 2.5 times the aggregate principal or convert principal and accrued interest on the notes to Series A Preferred Stock at the Original Series A Price of $1.2383573.

In the event the Company borrows, in the aggregate, $5,000,000, the note holders may convert and also receive a warrant to purchase a common stock share equal to 5% of the original principal amount of its note divided by the exercise price per share of the warrant, at the time of conversion.

7.	PREFERRED STOCK

Authorized preferred stock of Claros Diagnostics, Inc. consists of 14,128,753 shares of Class A. The rights attached to the preferred stock are as follows: voting, par value of $0.001 ($14,504,970 aggregate liquidation preference), cumulative dividend at the rate of $0.0868 per share and convertible into voting common stock. Unpaid cumulative dividends on the preferred stock amounted to $2,704,970 at December 31, 2010.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 13

8.	INCENTIVE OPTION PLAN

Effective December 20, 2006, the Board of Directors established the 2006 Stock Incentive Plan (the Plan). The Plan provides options to purchase new shares of the Companys common stock. Under the Plan, 3,608,610 stock options can be issued to founders, employees, advisors, consultants and board members of the Company.

The Company has elected to use the Black-Scholes-Merton option pricing model to determine the fair value of employee and non-employee stock options granted. Management has determined that the options issued in 2006, 2007, 2008 and 2009 have a calculated value of $0.13 per share and, has a calculated value of $0.27 per share in 2010. Total compensation cost associated with these options is $159,595 and will be recognized over the four year service period that began on the grant date. Compensation expense recognized on incentive options granted for the year ended December 31, 2010 and for the period October 27, 2004 (Inception) to December 31, 2010 was $26,214 and $102,832, respectively. Other expense recognized on non-employee stock option granted for the year ended December 31, 2010 and for the period October 27, 2007 (Inception) to December 31, 2010 was $10,807 and $57,196, respectively.

At December 31, 2010, unrecognized compensation costs related to non-vested options totaled $34,680. This amount will be recognized over the following years as follows:


Years	Amount
2011		15,797
2012		9,962
2013		6,191
2014		2,730

	$	34,680

The fair value per unit of options granted under the incentive option plan during the year ended December 31, 2010 was $0.27. This amount was determined using the Black-Scholes option-pricing model utilizing the following assumptions:


Risk-free interest rate		3.16% - 4.72%
Expected dividend yield
Expected volatility		20%
Expected life in years		10
Service period in years		4
Weight average calculated value of options granted		$0.14
Dividend yield		0%

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 14

8.	INCENTIVE OPTION PLANcontinued

The following table summarizes options outstanding at December 31, 2010, and the changes in options for the Period October 27, 2004 (Inception) to December 31, 2010.


	Options Reserved		Options			Weighted- Average Exercise Price
December 20, 2006		3,608,610				$	0.13
Reserved
Granted				1,771,499			0.13
Exercised				(311,653	)		0.13
Cancelled

December 31, 2006		3,608,610		1,459,846			0.13
Reserved
Granted				1,100,399			0.13
Exercised
Cancelled

December 31, 2007		3,608,610		2,560,245			0.13
Reserved
Granted				91,000			0.13
Exercised				(328,055	)		0.13
Cancelled

December 31, 2008		3,608,610		2,323,190			0.13
Reserved
Granted				323,500			0.13
Exercised				(131,220	)		0.13
Cancelled

December 31, 2009		3,608,610		2,515,470			0.13
Reserved
Granted				191,500			0.27
Exercised				(19,683	)		0.13
Cancelled

December 31, 2010		3,608,610		2,687,287		$	0.14

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 15

8.	INCENTIVE OPTION PLANcontinued

The following table summarizes information about stock options outstanding at December 31, 2010 and 2009:


Year Ending	Range of Exercise Prices		Number Outstanding		Number Exercisable		Weighted- Average Remaining Contractual Life		Weighted- Average Exercise Price
December 31, 2010	$	0.13-$0.27		3,166,245		2,427,036		0.95		0.14
December 31, 2009	$	0.13		2,974,745		1,677,209		1.76		0.13
December 31, 2008	$	0.13		2,651,245		1,005,648		2.48		0.13
December 31, 2007	$	0.13		2,560,245		364,962		3.43		0.13
December 31, 2006	$	0.13		1,459,846				4		0.13

During 2010, the Company received $2,559 from an employee upon exercise of options and recognized related tax benefits of $1,151. In accordance with the Company policy, the shares were issued from a pool of shares reserved for issuance under the plan.

During 2009, the Company received $17,058 from consultants upon exercise of options and recognized related tax benefits of $7,677. In accordance with the Company policy, the shares were issued from a pool of shares reserved for issuance under the plan.

During 2008, the Company received $42,647 from consultants upon exercise of options and recognized related tax benefits of $19,200. In accordance with the Company policy, the shares were issued from a pool of shares reserved for issuance under the plan.

During 2006, an employee exercised options in the amount of $40,515 and recognized related tax benefits of $18,232. In accordance with the Company policy, the shares were issued from a pool of shares reserved for issuance under the plan.

9.	COMMITMENTS

Operating Lease The Company leases an operating facility under a lease agreement expiring February 2012. Total monthly lease payments are approximately $9,200 per month.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 16

9.	COMMITMENTScontinued

Minimum future lease payments as of December 31, 2010 are as follows:


Years	Amount
2011	$	109,298
2012		18,217

	$	127,515

Rent expense under the lease for the year ended December 31, 2010 and for the period October 27, 2004 (Inception) to December 31, 2010 was $109,875 and $304,738, respectively.

Patent Rights License Agreement The Company entered into a Patent Rights License agreement with Harvard University (University). The agreement commenced November 2006 and continues on a Licensed Product-by-Licensed product and Country-by-Country basis until expiration of the last Patents Rights. The agreement allows the Company to make sublicenses to its affiliates. The Company can terminate the agreement at any time with a sixty days notice with no requirements of future payments.

As a consideration for the license granted, the Company:

Has issued to the University 2% of the outstanding common stock on a fully diluted basis upon completion of the Series A financing.

Shall pay to the University non-refundable annual license maintenance fees payable on January 1 of each year as stated below. Each license maintenance fee paid is creditable against the royalties due on Net Sales made during the calendar year following the due date.

Future license maintenance fees payments as of December 31, 2010 are as follows:


Years	Amount
2011	$	25,000
2012	$	50,000
2013	$	75,000
2014	$	100,000
Each subsequent calendar year for the remainder of the term	$	100,000

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2010 and for the Period

October 27, 2004 (Inception) to December 31, 2010

Page 17

9.	COMMITMENTScontinued

Per the agreement, the Company has agreed to pay to the University various amounts at the completion of certain milestones as described in the agreement. The payment amount of those milestones varies based on multiple criteria. No liability has been accrued at December 31, 2010 for those amounts.

The Company shall pay the University royalties of 3% of net sales for sales up to $200,000,000 and 2.5% of sales above $200,000,000.

The Company has agreed to pay the University various percentages for all Sublicense income based on the year of the Sublicense, where applicable.

10.

401(k) PROFIT SHARING PLAN

On January 1, 2008 the Company adopted a 401(k) profit sharing plan covering eligible employees as defined by the plan. Eligible employees may make pre-tax contributions up to the maximum allowed by law. The Company did not make a matching contribution for the year ended December 31, 2010. In addition, the plan provides for a profit sharing contribution by the Company at the discretion of the Board of Directors. For the year ended December 31, 2010 and for the period October 27, 2004 (Inception) to December 31, 2010 the Company did not make a profit sharing contribution to the plan.

SUPPLEMENTAL INFORMATION

LOGO

INDEPENDENT AUDITORS REPORT ON

CONSOLIDATING AND SUPPLEMENTAL INFORMATION

Board of Directors and Stockholders

Claros Diagnostics, Inc.

Woburn, Massachusetts

Our report on our audit of the basic consolidated financial statements of Claros Diagnostics, Inc. (A Development Stage Company) appears on page 1. This audit was made for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The consolidating information contained on pages 21 through 23 is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, results of operations, and cash flows of the individual companies. The supplemental information contained on page 24 is presented for additional analysis and is not a required part of the basic consolidated financial statements. Such consolidating and supplementary information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic consolidated financial statements taken as a whole.

LOGO

Kirkland Albrecht & Fredrickson, LLC

Braintree, Massachusetts

June 26, 2011

LOGO

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Balance Sheet

December 31, 2010

Page 20


	Claros US			Claros SARL	Eliminations	Consolidated
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	111,209		$	$	$	111,209
Refundable taxes		554					554
Prepaid expenses		18,552					18,552

Total current assets		130,315					130,315

PROPERTY AND EQUIPMENT, AT COST
Equipment		489,718					489,718
Leasehold improvements		117,816					117,816
Computer		74,302					74,302
Furniture and fixtures		43,283					43,283

		725,119					725,119
Less accumulated depreciations		320,904					320,904

Property and equipment, net		404,215					404,215

OTHER ASSETS:
Deposits		16,671					16,671
Accrued interest receivable from stockholder		5,950					5,950

Total other assets		22,621					22,621

	$	557,151		$	$	$	557,151

LIABILITES AND DEFICIT
CURRENT LIABILITES:
Convertible promissory note	$	2,000,000		$	$	$	2,000,000
Accounts payable		141,404					141,404
Accrued expenses and other current liabilities		204,641					204,641

Total current liabilities		2,346,045					2,346,045

DEFICIT:
Preferred stock, $0.001 par value, 14128,753 shares authorized, 9,528,753 issues and outstanding (liquidation preference of $14,504,970)		2,714,498					2,714,498
Common stock, $0.001 par value, 28,000,000 share authorized, 4,005,555 shares issued and outstanding		4,006					4,006
Additional paid-in capital		12,052,488					12,052,488
Stock subscription receivable		(40,515	)				(40,515	)
Deficit accumulated during the development stage		(16,519,371	)				(16,519,371	)

Total deficit		(1,788,894	)				(1,788,894	)

Total liabilities and deficit	$	557,151		$	$	$	557,151

See independent auditors report on consolidated supplemental information

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidating Statement of Operations

December 31, 2010

Page 21


	Claros US			Claros SARL			Eliminations			Consolidated
REVENUE	$			$			$			$

OPERATING EXPENSES:
General and administrative		3,184,089			9,409						3,193,498
Research and development		1,051,374									1,051,374
Marketing		12,527									12,527

		4,247,990			9,409						(4,257,399	)

Operating loss		(4,247,990	)		(9,409	)					(4,257,399	)

OTHER INCOME (EXPENSE):
Grant income		244,479									244,479
Interest expense		(64,000	)								(64,000	)
Dividend income		995									995
Interest income		95			17						112
Gain (loss on subsidiary liquidation		6,172			(6,172	)
Forgiveness of due from subsidiary		(50,000	)		50,000

Total other income, net		137,741			43,845						181,586

Net loss		(4,110,249	)		34,436						(4,075,813	)
Net income (loss) attributable to noncontrolling interest								(1,722	)		(1,722	)

Net loss attributable to Claros Diagnostics, Inc.	$	(4,110,249	)	$	34,436		$	(1,722	)	$	(4,077,535	)

See independent auditors report on consolidated supplemental information

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidating Schedule of General and Administrative Expenses

Year Ended December 31, 2010

Page 22


	Claros US		Claros SARL		Eliminations	Consolidated
Salaries	$	1,477,177	$		$	$	1,477,177
Consultants		485,486					485,486
Employee benefits		201,680					201,680
Patent legal		163,068					163,068
Depreciation		119,770					119,770
Rent		109,875					109,875
Payroll taxes		101,338					101,338
Patent licensing		112,414					112,414
Regulatory		83,264					83,264
Travel, meals and entertainment		77,920					77,920
Legal fees		44,096		4,889			48,985
Miscellaneous		40,116		79			40,195
Accounting services		32,670		4,352			37,022
Office		34,560		89			34,649
Recruiting		32,185					32,185
Utilities		28,313					28,313
Repairs and maintenance		25,110					25,110
Insurance		14,995					14,995
Safety		52					52

	$	3,184,089	$	9,409	$	$	3,193,498

See independent auditors report on consolidated supplemental information

Claros Diagnostics, Inc.

(A Development Stage Company)

Consolidated Financial Statements

and

Supplemental Information

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

LOGO

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

AND

SUPPLEMENTAL INFORMATION

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

AND

SUPPLEMENTAL INFORMATION

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

TABLE OF CONTENTS


		Page
Independent Auditors Report		1

Consolidated Financial Statements:

Consolidated Balance Sheet		2

Consolidated Statements of Operations		3

Consolidated Statements of Changes in Equity and Comprehensive Income		4-5

Consolidated Statements of Cash Flows		6

Notes to Consolidated Financial Statements		7-15

Supplemental Information:

Independent Auditors Report on Consolidating and Supplemental Information		17

Consolidating Balance Sheet		18-19

Consolidating Statement of Operations		20

Consolidating Schedule of General and Administrative Expenses		21

LOGO

INDEPENDENT AUDITORS REPORT

Board of Directors and Stockholders

Claros Diagnostics, Inc.

Woburn, Massachusetts

We have audited the accompanying consolidated balance sheet of Claros Diagnostics, Inc. (A Development Stage Company) as of December 31, 2009 and the related consolidated statements of operations, changes in equity and comprehensive income and cash flows for the year then ended and for the period October 27, 2004 (Inception) to December 31, 2009. These consolidated financial statements are the responsibility of the Companys management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Claros Diagnostics, Inc. (A Development Stage Company) as of December 31, 2009 and the results of their operations and their cash flows for the year then ended and for the period October 27, 2004 (Inception) to December 31, 2009, in conformity with accounting principles generally accepted in the United States of America.

Kirkland Albrecht & Fredrickson, LLC

Braintree, Massachusetts

August 4, 2010

LOGO

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Balance Sheet

December 31, 2009

Page 2


ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	2,119,182
Refundable taxes		14,153
Prepaid expenses		15,844

Total current assets		2,149,179
PROPOERTY AND EQUIPMENT, AT COST:
Equipment		342,848
Leasehold improvements		117,816
Computer		58,602
Furniture and fixtures		38,726

		557,992
Less accumulated depreciation		201,134

Property and equipment, net		356,858
OTHER ASSETS
Deposits		16,671
Accrued interest receivable from stockholder		5,855

Total other assets		22,526

	$	2,528,563

LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	130,316
Accrued expenses		151,687

Total current liabilities		282,003

EQUITY:
Claros Diagnostics, Inc.
Preferred stock, $0.001 par value, 9,528,753 shares authorized, issued and outstanding (liquidation preference of $13,677,874)		1,887,402
Common stock, $0.001 par value, 15,000,000 share authorized, 3,985,872 shares issued and outstanding		3,986
Additional paid-in capital		12,012,929
Stock subscription receivable		(40,515	)
Deficit accumulated during the development stage		(11,620,102	)
Accumulated other comprehensive income		4,604

Total Claros Diagnostics, Inc.		2,248,304
Noncontrolling interest		(1,744	)

Total equity		2,246,560

Total liabilities and equity	$	2,528,563

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statements of Operations

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 3


	2009			Cumulative for the Period October 27, 2004 (Inception) to December 31, 2009
REVENUES	$			$

OPERATING EXPENSES:
General and administrative		2,465,509			6,412,393
Research and development		1,338,627			3,863,305

		3,804,136			10,275,698

Operating loss		(3,804,136	)		(10,275,698	)
OTHER INCOME (EXPENSE):
Grant income		20,790			20,790
Dividend income		15,204			474,085
Interest income		2,053			11,173
Interest expense					(530	)
Competition income					26,000

Total other income, net		38,047			531,518

Net loss		(3,766,089	)		(9,744,180	)
Net income (loss) attributable to noncontrolling interest		347			1,952

Net loss attributable to Claros Diagnostics, Inc.	$	(3,765,742	)	$	(9,742,228	)

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statements of Change in Equity and Comprehensive Income

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 4


	Preferred Stock				Common Stock				Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
	Shares		Amount		Shares		Amount		Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
Balance at October 27, 2004 (Date of inception)			$				$		$		$			$			$			$			$
COMPREHENSIVE INCOME (LOSS)
Net Loss
Foreign currency translation adjustment

COMPREHENSIVE LOSS
Issuance of 2,925,000 shares of common stock						2,925,000		2,925																2,925

Balance, December 31, 2004						2,925,000		2,925																2,925
COMPREHENSIVE LOSS
Net Loss															(3,429	)								(3,429	)
Foreign currency translation adjustment

COMPREHENSIVE LOSS
Issuance of 7,500 shares of common stock						7,500		8																8

Balance, December 31, 2005						2,932,500		2,933							(3,429	)								(496	)
Sale of Subsidiary shares to non-controlling interest																					406			406
COMPREHENSIVE LOSS
Net Loss															(158,630	)					(49	)		(158,679	)
Foreign currency translation adjustment																		(396	)		150			(246	)

COMPREHENSIVE LOSS																		(396						(158,925	)
Issuance of 594,097 shares of common stock						594,097		594		40,203														40,797
Stock subscription receivable												(40,515	)											(40,515	)
Issuance of 6,298,667 shares of Series A preferred stock		6,298,667		6,298						7,793,702														7,800,000
Accretion of dividends on Series A preferred stock				16,477											(16,477	)

Balance, December 31, 2006		6,298,667		22,775		3,526,597		3,527		7,833,905		(40,515	)		(178,536	)		(396	)		507			7,641,267

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statements of Change in Equity and Comprehensive Incomecontinued

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 5


	Preferred Stock				Common Stock				Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
	Shares		Amount		Shares		Amount		Additional Paid-in Capital		Stock Subscription Receivable			Deficit Accumulated During the Development Stage			Accumulated Other Comprehensive Income			Non-controlling Interest			Total
Balance, December 31, 2006		6,298,667		22,775		3,526,597		3,527		7,833,905		(40,515	)		(178,536	)		(396	)		507			7,641,267
COMPREHENSIVE INCOME (LOSS)
Net Loss															(1,721,663	)					(1,326	)		(1,722,989	)
Foreign currency translation adjustment																		2,666			(34	)		2,632

COMPREHENSIVE LOSS																		2,270						(1,720,357	)
Accretion of dividends on Series A preferred stock				546,724											(546,724	)
Incentive option based compensation										39,001														39,001

Balance, December 31, 2007		6,298,667		569,499		3,526,597		3,527		7,872,906		(40,515	)		(2,446,923	)		2,270			(853	)		5,959,911
COMPREHENSIVE INCOME (LOSS)
Net Loss															(4,092,764	)					(284	)		(4,093,048	)
Foreign currency translation adjustment																		2,492			(111	)		2,381

COMPREHENSIVE LOSS																		4,762						(4,090,667	)
Issuance of 328,055 shares of common stock						328,055		328		42,319														42,647
Accretion of dividends on Series A preferred stock				546,724											(546,724	)
Stock-based based compensation expense										47,909														47,909

Balance, December 31, 2008		6,298,667		1,116,223		3,854,652		3,855		7,963,134		(40,515	)		(7,086,411	)		4,762			(1,248	)		1,959,800
COMPREHENSIVE INCOME (LOSS)
Net Loss															(3,765,742	)					(347	)		(3,766,089	)
Foreign currency translation adjustment																		(158	)		(149	)		(307	)

COMPREHENSIVE LOSS																		4,604						(3,766,396	)
Issuance of 3,230,086 shares of Series A preferred stock		3,230,086		3,230						3,996,770														4,000,000
Issuance of 131,220 shares of common stock						131,220		131		16,927														17,058
Accretion of dividends on Series A preferred stock				767,949											(767,949	)
Incentive option based compensation										36,097														36,097

Balance, December 31, 2009		9,528,753		1,887,402		3,985,872		3,986		12,012,928		(40,515	)		(11,620,102	)		4,604			(1,744	)		2,246,559

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statements of Cash Flows

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 6


	2009			Cumulative for the Period October 27, 2004 (Inception) to December 31, 2009
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,766,089	)	$	(9,744,180	)
Adjustments to reconcile net loss to net cash provided (used) by operating activities:
Incentive option based compensation		36,097			123,007
Depreciation		93,215			201,136
Minority interests share of loss		(347	)		(1,952	)
Changes in assets and liabilities:
(Increase) decrease in:
Accrued interest receivable from a stockholder		(2,028	)		(5,855	)
Prepaid expenses and other current assets		(2,470	)		(15,844	)
Refundable taxes		1,176			(14,153	)
Decrease (increase) in:
Accounts payable		(146,700	)		143,468
Accrued expenses and other current liabilities		107,532			153,452

Net cash used by operating activities		(3,679,614	)		(9,160,921	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment		(258,258	)		(557,991	)
Deposits		600			(16,671	)

Net cash used by investing activities		(257,658	)		(574,662	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on stockholder notes payable					(24,877	)
Advances of stockholder notes payable					24,877
Proceeds from issuance of common stock		17,059			62,933
Proceeds from issuance of preferred stock		4,000,000			11,800,000

Net cash provided by financing activities		4,017,059			11,862,933

EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS		(1,113	)		(8,168	)

NET INCREASE IN CASH		78,674			2,119,182
CASH, BEGINNING OF PERIOD		2,040,508

CASH, END OF PERIOD	$	2,119,182		$	2,119,182

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFROMATION:
Cash paid during the year for:
Interest	$			$	980

Income taxes	$			$

See notes to the consolidated financial statements.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 7

1.	ORGANIZATION

Claros Diagnostics, SARL (SARL), is a majority owned subsidiary in Switzerland (Neuchatel) and was organized on August 7, 2006. Its principal business activity is to develop, manufacture and sell medical diagnostic devices.

The minority interest represents the minority stockholders interest in SARL (a Subsidiary). The minority stockholder of SARL is a stockholder of Claros Diagnostics, Inc. The Company owns 95% of the Subsidiary.

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation  The accompanying consolidated financial statements for the year ended December 31, 2009 and for the period October 24, 2004 (inception) to December 31, 2009 are prepared in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic Consolidation. These consolidated financial statements include the accounts of the Company and its majority owned subsidiary SARL for the year ended December 31, 2009. All significant inter-company balances and transactions have been eliminated.

Foreign Subsidiary  Statements of the accounts of Claros Diagnostics, SARL are translated into U.S. dollars at the prevailing rate of exchange at the balance sheet date; whereas revenue and expense categories have been translated at the average of foreign exchange rates prevailing throughout the fiscal year. The net assets of the foreign subsidiary included in the consolidated balance sheets amounted to a deficit of $34,884 at December 31, 2009. The subsidiary recorded a net loss of $6,945 for the year ended December 31, 2009.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 8

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIEScontinued


Asset		Years
Equipment		5
Leasehold improvements		5
Computer		3
Furniture and fixtures		7

The Company accounts for uncertain tax positions in accordance with FASB ASC Topic Income Taxes. FASB ASC Topic Income Taxes prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company adopted the provisions of the FASB ASC Income Taxes Topic on January 1, 2009. There was no impact on total liabilities or equity as a result of this adoption.

Valuation of Long-lived Assets The Company accounts for the valuation of long-lived assets in accordance with the FASB ASC Topic Property, Plant, and Equipment. The FASB ASC Topic Property, Plant, and Equipment requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reportable at the lower of the carrying amount or fair value, less costs to sell. At December 31, 2009, the Company has determined that no long-lived assets are impaired.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 9

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIEScontinued

Exchange Rate Gains and Losses Aggregate transaction gains and losses on foreign exchange rates included in consolidated net loss for the year ended December 31, 2009 were not material.

Research and Development Research and development costs are charged to expense as incurred in accordance with FASB ASC Topic Research and Development. Research and development costs include consulting, material and supplies. For the year ended December 31, 2009 and the period October 27, 2004 (Inception) to December 31, 2009 research and development costs were $1,338,627 and $3,863,305 respectively, and are included in the other expense on the accompanying consolidated statements of operations.

Comprehensive Income Comprehensive income for the Company and SARL consist of foreign currency translation adjustments. Accumulated other comprehensive income is disclosed as a separate component of stockholders equity and consists entirely of foreign currency translation adjustments at December 31, 2009.

Incentive Option Plan The Company has an incentive option plan which is described in Note 6. FASB ASC Topic Compensation-Stock Compensation requires that the cost resulting for all share-based payment transactions be recognized in the consolidated financial statements. This statement requires the entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide services in exchange for the award of the vesting period. FASB ASC Topic Compensation-Stock Compensation permits entities to use any option-pricing model that meets the fair value objective of the Statement. Compensation cost on options granted has been measured using the fair value of an award on the grant date using the Black-Scholes valuation model, and is recognized in the income statement over the service period, which is usually the vesting period of the option.

Recently Issued Accounting Guidance  On January 1, 2009, the Company adopted the new guidance located in FASB Topic Consolidation that relates to noncontrolling interest. Accordingly, for consolidated subsidiaries that are less than wholly owned, the third-party holdings of equity interests are referred to as noncontrolling interest. The portion for net income attributable to noncontrolling interest for such subsidiaries is presented as net income (loss) attributable to noncontrolling interest on the consolidated financial statements of operations, and the portion of the stockholders equity of such subsidiaries is presented as noncontrolling interest on the consolidated balance sheet and consolidated statement of changes in equity. This recent pronouncement also requires the Company to allocate losses to the noncontrolling interest even if the noncontrolling interest has a deficit balance.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 10

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIEScontinued

Subsequent Events  The Company has evaluated all events subsequent to the balance sheet date of December 31, 2009, through the date which the financial statements were available to be issued, August 4, 2010, and has determined that there are no additional subsequent events, except as noted in note 9, that require disclosure under FASB ASC Topic Subsequent Events.

3.	PROVISION FOR INCOME TAXES

Amounts for deferred tax asset and liability are as follows:


Deferred tax asset	$	4,507,450
Valuation allowance		(4,507,450	)

	$

The deferred tax asset consists of the following temporary differences:


Depreciation	$	(28,290	)
Net operating loss carryforward		3,766,345
R & D credits		718,085
Stock option		51,310
Valuation allowance		(4,507,450	)

	$

At December 31, 2009, the Company has available net operating losses (NOL) carry forward for federal and state income tax purposes of approximately $8,950,440 and $9,197,655, respectively, which expire, if unused at various times through 2029. The Companys ability to utilize these NOL may be limited under Internal Revenue Code Section 382.

4.	RELATED PARTY TRANSACTIONS

Stock Subscription Receivable  At December 31, 2009, the Company has a promissory note receivable from a stockholder of the Company for his stock subscription for an amount of $40,515. The amount is included as a reduction of the stockholders equity on the accompanying consolidated balance sheet. The note bears interest at the Applicable Federal Rate and shall be compounded annually. At December 31, 2009, there was $5,855 of accrued interest receivable from a stockholder, included in the other assets on the accompanying consolidated balance sheet. The principal loan amount and the accrued interest are due December 2011.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 11

5.	PREFERRED STOCK

Authorized preferred stock of Claros Diagnostics, Inc. consists of 9,528,753 shares of Class A. The rights attached to the preferred stock are as follows: voting, par value of $0.001 ($13,677,874 aggregate liquidation preference), cumulative dividend at the rate of $0.0868 per share and convertible into voting common stock. Unpaid cumulative dividends on the preferred stock amounted to $1,877,874 at December 31, 2009.

6.	INCENTIVE OPTION PLAN

Effective December 20, 2006, the Board of Directors established the 2006 Stock Incentive Plan (the Plan). The Plan provides option to purchase new shares of the Companys common stock. Under the Plan, 3,608,610 stock options can be issued to founders, employees, advisors, consultants and board members of the Company.

The Company has elected to use the Black-Scholes-Merton option pricing model to determine the fair value of employee and non-employee stock options granted. Management has determined that the options issued in 2006, 2007, 2008 and 2009 have a calculated value of $0.13 per share. Total compensation cost associated with these options is $149,651 and will be recognized over the four year service period that began on the grant date. Compensation expense recognized on employee stock options granted for the year ended December 31, 2009 and for the period October 27, 2004 (Inception) to December 31, 2009 was $28,470 and $76,347, respectively. Other expense recognized on non-employee stock option granted for the year ended December 31, 2009 and for the period October 27, 2007 (Inception) to December 31, 2009 was $7,627 and $26,186, respectively.

At December 31, 2009, unrecognized compensation costs related to non-vested options totaled $47,118. This amount will be recognized over the following years as follows:


Years	Amount
2010	$	32,980
2011		8,298
2012		4,788
2013		1,052

	$	47,118

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 12

6.	INCENTIVE OPTION PLANcontinued

The fair value per unit of options granted under the incentive option plan during the year ended December 31, 2009 was $0.13. This amount was determined using the Black-Scholes option-pricing model utilizing the following assumptions:


Risk-free interest rate		3.16% - 4.72%
Expected dividend yield
Expected volatility		20%
Expected life in years		10
Service period in years		4
Weight average calculated value of options granted		$0.13
Dividend yield		0%

The following table summarizes options outstanding at December 31, 2009, and the changes in options for the Period October 27, 2004 (Inception) to December 31, 2009.


			Weighted Average Exercise Price Per Share
Total options available for grant at
December 20, 2006	3,608,610		$

Options granted - 2006	1,771,499		$	0.13
Options exercised - 2006	(311,653	)		0.13
Options granted - 2007	1,100,399			0.13
Options granted - 2008	91,000			0.13
Options exercised - 2008	(328,055	)		0.13
Options granted - 2009	313,500			0.13
Options exercised - 2009	(131,220	)		0.13

Total options outstanding at December 31, 2009	2,505,470		$	0.13

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 13

6.	INCENTIVE OPTION PLANcontinued

During 2009, the Company received $17,059 from consultants upon exercise of options and recognized related tax benefits of $7,677. In accordance with the Company policy, the shares were issued from a pool of shares reserved for issuance under the plan.

During 2006, the Company received $40,515 from an employee upon exercise of options and recognized related tax benefits of $18,232. In accordance with the Company policy, the shares were issued from a pool of shares reserved for issuance under the plan.

7.	COMMITMENTS

Operating Lease The Company leases an operating facility under a lease agreement expiring February 2012. Total monthly lease payments are approximately $8,033 per month.

Minimum future lease payments as of December 31, 2009 are as follows:


Years	Amount
2010	$	96,044
2011		96,044
2012		16,007

	$	208,095

Rent expense under the lease for the year ended December 31, 2009 and for the period October 27, 2004 (Inception) to December 31, 2009 was $96,949 and $194,863, respectively.

As a consideration for the license granted, the Company:

Has issued to the University 2% of the outstanding common stock on a fully diluted basis upon completion of the Series A financing.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 14

7.	COMMITMENTScontinued

Patent Rights License Agreementcontinued 

Future license maintenance fees payments as of December 31, 2009 are as follows:


Years	Amount
2010	$	10,000
2011	$	25,000
2012	$	50,000
2013	$	75,000
2014	$	100,000
Each subsequent calendar year for the remainder of the term	$	100,000

The Company shall pay the University royalties of 3% of net sales for sales up to $200,000,000 and 2.5% of sales above $200,000,000.

The Company has agreed to pay the University various percentages for all Sublicense income based on the year of the Sublicense, where applicable.

8.	401(k) PROFIT SHARING PLAN

On January 1, 2008 the Company adopted a 401(k) profit sharing plan covering eligible employees as defined by the plan. Eligible employees may make pre-tax contributions up to the maximum allowed by law. The Company did not make a matching contribution for the year ended December 31, 2009. In addition, the plan provides for a profit sharing contribution by the Company at the discretion of the Board of Directors. For the year ended December 31, 2009 and for the period October 27, 2004 (Inception) to December 31, 2009 the Company did not make a profit sharing contribution to the plan.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

Year Ended December 31, 2009 and for the Period

October 27, 2004 (Inception) to December 31, 2009

Page 15

9.	SUBSEQUENT EVENT

On June 17, 2010, the Board of Directors of Claros Diagnostics, Inc. amended and restated the certificate of incorporation of the Corporation as followed: increase the number of authorized shares of common stock from 18,500,000 shares to 28,000,000 shares and increase the number of authorized shares of preferred stock from 9,528,753 shares to 14,128,753 shares.

On June 21, 2010, the Corporation entered into a $5,000,000 convertible promissory note with some of the Corporations stockholders. The note can be accessed at the discretion of the Corporation by tranches. Each tranche bears interest at 8% from the date it is accessed. Each note holder has certain conversion rights which vary based on meeting certain financial criteria. The terms are stated in their respective convertible promissory note agreement. As of the report date, only $1,000,000 of the $5,000,000 convertible promissory note has been accessed by the Corporation.

SUPPLEMENTAL INFORMATION

LOGO

INDEPENDENT AUDITORS REPORT ON

CONSOLIDATING AND SUPPLEMENTAL INFORMATION

Board of Directors and Stockholders

Claros Diagnostics, Inc.

Woburn, Massachusetts

Our report on our audit of the basic consolidated financial statements of Claros Diagnostics, Inc. (A Development Stage Company) appears on page 1. This audit was made for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The consolidating information contained on pages 18 through 20 is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, results of operations, and cash flows of the individual companies. The supplemental information contained on page 21 is presented for additional analysis and is not a required part of the basic consolidated financial statements. Such consolidating and supplementary information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic consolidated financial statements taken as a whole.

LOGO

Kirkland Albrecht & Fredrickson, LLC

Braintree, Massachusetts

August 4, 2010

LOGO

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Balance Sheet

December 31, 2009

Page 18


	Claros US		Claros SARL		Eliminations			Consolidated
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	2,089,898	$	29,284	$			$	2,119,182
Due from related party		50,000				(50,000	)
Refundable taxes		14,153							14,153
Prepaid expenses		15,844							15,844

Total current assets		2,169,895		29,284		(50,000	)		2,149,179

PROPERTY AND EQUIPMENT, AT COST
Equipment		342,848							342,848
Leasehold improvements		117,816							117,816
Computer		58,602							58,602
Furniture and fixtures		38,726							38,726

		557,992							557,992
Less accumulated depreciations		201,134							201,134

Property and equipment, net		356,858							356,858

OTHER ASSETS:
Deposits		16,671							16,671
Accrued interest receivable from stockholder		5,855							5,855
Investment in Claros Diagnostics SARL		8,122				(8,122	)

Total other assets		30,648				(8,122	)		22,526

	$	2,557,401	$	29,284	$	(58,122	)	$	2,528,563

See independent auditors report on consolidated supplemental information.


		Page 19


	Claros US			Claros SARL			Eliminations			Consolidated
LIABILITES AND EQUITY
CURRENT LIABILITES:
Accounts payable	$	130,316		$			$			$	130,316
Due to related party					57,790			(57,790	)
Accrued expenses and other current liabilities		145,309			6,378						151,687

Total current liabilities		275,625			64,168			(57,790	)		282,003

EQUITY:
Claros Diagnostics, Inc.
Preferred stock, $0.001 par value, 9,528,753 shares authorized, issued and outstanding (liquidation preference of $13,677,874)		1,887,402									1,887,402
Common stock, $0.001 par value, 28,000,000 share authorized, 3,985,872 shares issued and outstanding		3,986			8,122			(8,122	)		3,986
Additional paid-in capital		12,012,929									12,012,929
Stock subscription receivable		(40,515	)								(40,515	)
Deficit accumulated during the development stage		(11,582,026	)		(40,028	)		1,952			(11,620,102	)
Accumulated other comprehensive income					(2,978	)		7,582			4,604

Total Claros Diagnostics, Inc.		2,281,776			(34,884	)		1,412			2,248,304

Noncontrolling interest								(1,744	)		(1,744	)

Total equity		2,281,776			(34,884	)		(332	)		2,246,560

Total liabilities and equity	$	2,557,401		$	29,284		$	(58,122	)	$	2,528,563

See independent auditors report on consolidated supplemental information.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidated Statement of Operations

Year ended December 31, 2009

Page 20


	Claros US			Claros SARL			Eliminations		Consolidated
REVENUE	$			$			$		$

OPERATING EXPENSES:
General and administrative		2,458,539			6,970					2,465,509
Research and development		1,338,627								1,338,627

		3,797,166			6,970					3,804,136

Operating loss		(3,797,166	)		(6,970	)				(3,804,136	)

OTHER INCOME (EXPENSE):
Grant income		20,790								20,790
Dividend income		15,204								15,204
Interest income		2,028			25					2,053

Total other income, net		38,022			25					38,047

Net loss		(3,759,144	)		(6,945	)				(3,766,089	)
Net income (loss) attributable to noncontrolling interest								347		347

Net loss attributable to Claros Diagnostics, Inc.	$	(3,759,144	)	$	(6,945	)	$	347	$	(3,765,742	)

See independent auditors report on consolidated supplemental information.

CLAROS DIAGNOSTICS, INC.

(A Development Stage Company)

Consolidating Schedule of General and Administrative Expenses

Year ended December 31, 2009

Page 21


	Claros US		Claros SARL		Eliminations	Consolidated
Salaries	$	1,213,157	$		$	$	1,213,157
Consultants		370,492					370,492
Patent legal		141,784					141,784
Employee benefits		124,044					124,044
Rent		96,949					96,949
Depreciation		93,215					93,215
Legal fees		91,540					91,540
Payroll taxes		80,903					80,903
Patent licensing		52,633					52,633
Accounting services		28,450		6,894			35,344
Miscellaneous		34,667		76			34,743
Travel, meals and entertainment		32,911					32,911
Office		29,223					29,223
Utilities		21,389					21,389
Repairs and maintenance		16,510					16,510
Insurance		12,605					12,605
Recruiting		12,400					12,400
Safety		4,048					4,048
Promotional materials		1,505					1,505
Taxes, other		114					114

	$	2,458,539	$	6,970	$	$	2,465,509

See independent auditors report on consolidated supplemental information.

Claros Diagnostics, Inc.

(A Development Stage Company)

Condensed Consolidated Balance Sheets

As of September 30, 2011 and September 30, 2010

(unaudited)

(in thousands, except share and per share data)


	September 30, 2011			September 30, 2010
ASSETS
Current assets
Cash and cash equivalents	$	77		$	884
Prepaid expenses and other current assets		10			2

Total current assets		87			886
Property and equipment, net		349			405
Other assets		24			23

TOTAL ASSETS	$	460		$	1,314

LIABILITIES AND SHAREHOLDERS DEFICIT
Current liabilities
Convertible promissory note and notes payable	$	4,299		$	2,000
Accounts payable		611			91
Accrued expenses		106			3

Total current liabilities		5,016			2,094
Commitments and contingencies
DEFICIT
Preferred Stock - $0.001 par value, 14,128,753 shares authorized, 9,528,753 issued and outstanding at September 30, 2011 and 2010		3,335			2,507
Common Stock - $0.001 par value, 500,000,000 shares authorized, 4,005,555 shares issued		4			4
Additional paid-in capital		12,057			12,057
Stock subscription receivable		(41	)		(41	)
Deficit accumulated during the development stage		(19,911	)		(15,307	)

Total deficit		(4,556	)		(780	)

Total liabilities and deficit	$	460		$	1,314

Claros Diagnostics, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Operations

For the nine months ended September 30, 2011 and 2010

and for the Period October 27, 2004 (Inception) to September 31, 2011 and 2010

(unaudited)

(in thousands)


	September 30, 2011			September 30, 2010			Cumulative for the period October 27, 2004 (Inception) to September 30, 2011			Cumulative for the period October 27, 2004 (Inception) to September 30, 2010
Revenue	$			$			$			$
Cost of goods sold

Gross margin
Operating expenses
Selling, general and administrative		2,349			2,261			11,967			8,673
Research and development		514			811			5,429			4,674

Total operating expenses		2,863			3,072			17,396			13,347

Operating loss		(2,863	)		(3,072	)		(17,396	)		(13,347	)
Other (expense) income, net		(4	)		1			710			532

Loss before income taxes		(2,867	)		(3,071	)		(16,686	)		(12,815	)
Income tax provision

Net loss	$	(2,867	)	$	(3,071	)	$	(16,686	)	$	(12,815	)

Claros Diagnostics, Inc.

(A Development Stage Company)

Condensed Consolidated Statements Cash Flows

For the nine months ended September 30, 2011 and 2010

and for the Period October 27, 2004 (Inception) to September 31, 2011 and 2010

(unaudited)


	For the nine months ended September 30, 2011			For the nine months ended September 30, 2010			Cumulative for the Period October 27, 2004 (Inception) to September 30, 2011			Cumulative for the Period October 27, 2004 (Inception) to September 30, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2,867	)	$	(3,071	)	$	(16,687	)	$	(12,815	)
Adjustments to reconcile net loss to net cash provided (used) by operating activities:
Incentive option based compensation		95			27			255			150
Depreciation		75			90			396			291
Changes in assets and liabilities:
(Increase) decrease in:
Prepaid expenses and other current assets		(9	)		(28	)		(28	)		(57	)
Accounts payable		(35	)		(39	)		120			104
Accrued expenses and other current liabilities		406			(148	)		606			(3	)

Net cash used by operating activities		(2,335	)		(3,169	)		(15,338	)		(12,330	)


CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment		(3	)		(66	)		(728	)		(624	)
Deposits								(17	)		(17	)

Net cash used by investing activities		(3	)		(66	)		(745	)		(641	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory note		2,299			2,000			4,299			2,000
Payments on stockholder notes payable								(25	)		(25	)
Advances of stockholder notes payable								25			25
Proceeds from issuance of common stock		5						70			63
Proceeds from issuance of preferred stock								11,800			11,800

Net cash provided by financing activities		2,304			2,000			16,169			13,863

EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS								(9	)		(8	)

NET INCREASE (DECREAE IN CASH AND CASH EQUIVALENTS		(34	)		(1,235	)		77			884
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		111			2,119

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	77		$	884		$	77		$	884

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the year for:
Interest
Income taxes	$			$			$	1		$	1

	$						$			$

Form: 8-K/A

Documents